RxDoctor Payments Data

Michael Todinca, MD

Neuromuscular Medicine · Jacksonville Beach, FLNPI 1770016800

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Argenx US, Inc. at 43.5% of the total. 2025 is the largest year on record at $11,424, more than ten times the $414 reported in 2022.

$15,936in general payments, 2019–2025

Across 265 payments — averaging $60.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$7K
  • AstraZeneca$3K
  • AbbVie$564
  • Amgen$519
  • ANI Pharmaceuticals, Inc.$391
  • Novartis$310
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$7,40046%
  • Travel & lodging$1,56110%
  • Food & beverage$6,85043%
  • Education$1251%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$121,055
Medicare patients
331
Services billed
1,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4658$585,177
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5019$227,589
Nurtec OdtRimegepant Sulfate13$17,725
Gabapentin287$4,710
Pyridostigmine Bromide39$3,005
Pregabalin109$2,408
Memantine Hcl47$1,146
Duloxetine Hcl51$1,009
Carbidopa-LevodopaCarbidopa/Levodopa46$808
Levetiracetam21$634
Donepezil Hcl19$372
Methylprednisolone42$358
Propranolol Hcl19$327
Amitriptyline Hcl11$305
Sodium Chloride0.9 % Sodium Chloride27$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$25$227,58919 claims
PfizerNurtec Odt$129$17,72513 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$100$3,00539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Jacksonville Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →